(Q37619494)

21 August 2017

1 reference

title

Cerebrolysin: a review of its use in dementia (English)

1 reference

21 August 2017

0 references

1

Greg L Plosker

1 reference

21 August 2017

Serge Gauthier

2

1 reference

21 August 2017

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

26

1 reference

21 August 2017

11

1 reference

21 August 2017

893-915

1 reference

https://scigraph.springernature.com/pub.10.2165/11203320-000000000-00000

21 August 2017

0 references

cites work

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11203320-000000000-00000

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11203320-000000000-00000

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11203320-000000000-00000

Galantamine extended release.

21 January 2018

1 reference

12 December 2020

The drug cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats.

1 reference

12 December 2020

Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons

1 reference

12 December 2020

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.

1 reference

12 December 2020

Global prevalence of dementia: a Delphi consensus study

1 reference

12 December 2020

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

1 reference

12 December 2020

Does analysis using "last observation carried forward" introduce bias in dementia research?

1 reference

12 December 2020

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease

1 reference

12 December 2020

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

12 December 2020

Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis.

1 reference

12 December 2020

Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type

1 reference

12 December 2020

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study).

1 reference

12 December 2020

Donepezil: in vascular dementia

1 reference

12 December 2020

Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures.

1 reference

12 December 2020

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature

1 reference

12 December 2020

The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease.

1 reference

12 December 2020

Therapeutic results with Cerebrolysin in the treatment of dementia.

1 reference

12 December 2020

BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain.

1 reference

12 December 2020

[Experience with using high doses of cerebrolysin in vascular dementia]

1 reference

12 December 2020

Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats.

1 reference

12 December 2020

Effects of brain tissue hydrolysate on synaptic transmission in the hippocampus

1 reference

12 December 2020

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.

1 reference

12 December 2020

In vitro synaptotrophic effects of Cerebrolysin in NT2N cells.

1 reference

12 December 2020

Effects of NGF, b-FGF, and cerebrolysin on water maze performance and on motor activity of rats: short- and long-term study.

1 reference

12 December 2020

ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease

1 reference

12 December 2020

Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.

1 reference

12 December 2020

Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity

1 reference

12 December 2020

Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks

1 reference

12 December 2020

The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.

1 reference

12 December 2020

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

12 December 2020

The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats.

1 reference

12 December 2020

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

1 reference

12 December 2020

A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration

1 reference

12 December 2020

Rivastigmine. A review of its use in Alzheimer's disease.

1 reference

12 December 2020

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

1 reference

12 December 2020

Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 6-week-old rats.

1 reference

12 December 2020

Memantine: a review of its use in Alzheimer's disease

1 reference

12 December 2020

Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.

1 reference

12 December 2020

The short-term influence of b-FGF, NGF and Cerebrolysin on the memory impaired after fimbria-fornix lesion.

1 reference

12 December 2020

Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review

1 reference

12 December 2020

Donepezil: a review of its use in Alzheimer's disease

1 reference

12 December 2020

Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.

1 reference

12 December 2020

Biomarkers for Alzheimer's disease

1 reference

12 December 2020

Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain

1 reference

12 December 2020

Amyloid-beta immunisation for Alzheimer's disease

1 reference

12 December 2020

[Mild forms of multi-infarct dementia: effectiveness of cerebrolysin].

1 reference

12 December 2020

Neurotrophic factors in neurodegenerative disorders : potential for therapy

1 reference

12 December 2020

Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons

1 reference

12 December 2020

Nerve growth factor treatment in dementia

1 reference

12 December 2020

Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion.

1 reference

12 December 2020

Brain tissue hydrolysate acts on presynaptic adenosine receptors in the rat hippocampus

1 reference

12 December 2020

Pharmacotherapy of Alzheimer disease

1 reference

12 December 2020

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

1 reference

12 December 2020

Pituitary adenylate cyclase-activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat.

1 reference

12 December 2020

Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin

1 reference

12 December 2020

A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons

1 reference

12 December 2020

Disease-modifying therapies in Alzheimer's disease: how far have we come?

1 reference

12 December 2020

Galantamine: a review of its use in Alzheimer's disease

1 reference

12 December 2020

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

1 reference

12 December 2020

Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old rats

1 reference

12 December 2020

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease

1 reference

12 December 2020

Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides

1 reference

12 December 2020

Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin

1 reference

12 December 2020

Brain-derived peptides inhibit synaptic transmission via presynaptic GABAB receptors in CA1 area of rat hippocampal slices.

1 reference

12 December 2020

The long-term effect of NGF, b-FGF and Cerebrolysin on the spatial memory after fimbria-fornix lesion in rats.

1 reference

12 December 2020

Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.

1 reference

12 December 2020

Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection

1 reference

12 December 2020

10.2165/11203320-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

19848437

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

19848437